Genmab — Juli 2016
-
-
Vi slutter højt.
-
Enorm volumen sådan en sommerdag...
-
- Luk i HOD.
- Luk i HOD.
-
Det plejer det at blive efter HOD.
-
Lidt om Myeloma i US: http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/all
-
-
Commenting on the breakthrough status, Craig L. Tendler, MD, vice president, Late-Stage Development and Global Medical Affairs for Oncology, Hematology, and Supportive Care at Janssen, said, “This is an important recognition of the transformative potential of daratumumab and its possible benefit as a backbone therapy in combination with 2 of the most widely used regimens for multiple myeloma.
-
-
We look forward to working closely with the FDA throughout the review process and remain committed to exploring the full clinical benefit of this promising compound for multiple myeloma patients who
are eagerly awaiting new treatment options.” -
Tak for links Royal og Budweis.
-
Vi skal jo starte et sted - så må vi udvide til andre indikationer. F.eks NSCLC er der jo et reelt kapløb igang, hvor vi er med på en duobody, Tisotumab må da også gerne lige vise noget og det, jeg ser mest hen til, er faktisk om Ofa kan gøre noget ved RMS.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind